Filing Details

Accession Number:
0001144204-14-059582
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-03 22:01:15
Reporting Period:
2014-10-01
Filing Date:
2014-10-03
Accepted Time:
2014-10-03 21:01:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1353128 Gayle Barbara Duncan C/O Intercept Pharmaceuticals, Inc.
450 W. 15Th Street, Suite 505
New York NY 10011
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-10-01 1,299 $0.00 16,107 No 4 M Direct
Common Stock Acquisiton 2014-10-01 1,000 $31.90 17,107 No 4 M Direct
Common Stock Disposition 2014-10-01 900 $232.92 16,207 No 4 S Direct
Common Stock Disposition 2014-10-01 100 $234.87 16,107 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2014-10-01 1,299 $0.00 1,299 $0.00
Common Stock Options to Purchase Common Stock Disposition 2014-10-01 1,000 $0.00 1,000 $31.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,490 No 4 M Direct
15,875 2023-05-07 No 4 M Direct
Footnotes
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 17, 2014.
  2. Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
  3. On November 16, 2012, the reporting person was granted 20,769 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on October 1, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from January 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
  4. This option to purchase common stock was originally granted to the reporting person on May 7, 2013 (original amount: 22,500 shares). 25% of the shares of common stock underlying this option vested on January 1, 2014, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2017 (representing the vesting of approximately 2.0833% of the shares of common stock initially underlying these options on each such vesting date), subject to the terms and conditions of the award and the 2012 Plan.
  5. This transaction was executed in multiple trades at prices ranging from $232.83 to $233. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.